Thesis
Reverse merger turns Passage Bio into Remix Therapeutics after FDA blocked PBFT02's path; REM-422 Phase 2 ACC data in 2027 is the new make-or-break event
Passage Bio, built around PBFT02, a gene therapy for a rare inherited dementia, is being subsumed into Remix Therapeutics via reverse merger after FDA rejected a single-arm registrational path and required a randomized trial the company could not feasibly run. What survives is REM-422, an mRNA degrader in a registrational Phase 2 for adenoid cystic carcinoma, an unproven asset in a new modality with no efficacy data yet disclosed. The thesis now resolves entirely on whether REM-422 generates convincing ACC response data in 2027, with no approved therapies in that setting but an unvalidated mechanism carrying the full weight of the combined company.
Focus
REM-422 Phase 2 registrational trial data in ACC
2027
Bull
A positive outcome would show durable objective response rates or disease stabilization in ACC patients that meet pre-specified registrational endpoints, validating REM-422's mRNA degrader platform in a setting with very limited therapeutic options. Combined with Orphan Drug and Fast Track designations, compelling data could support an accelerated approval pathway and position the combined company as the first targeted therapy approved specifically for ACC, representing a significant re-rating event.
Bear
The most likely failure modes include insufficient single-arm response rates to meet the registrational bar without a randomized comparator — a risk already demonstrated by the FDA's stance on PBFT02 — or toxicity signals that limit dosing in what is a chronically managed cancer population. ACC is a slow-growing tumor where objective response can be hard to demonstrate in a time-limited Phase 2 window, and any signal of activity without clear durability could leave the regulatory path ambiguous rather than cleanly positive.
Unlock the full thesis for PASG.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.